Skip to main content

DCDD heart transplantation with thoraco-abdominal normothermic regional perfusion and static cold storage: The experience in Spain.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2025-02-25PubMed
Total: 81.5Innovation: 8Impact: 9Rigor: 8Citation: 8

Summary

In a nationwide prospective cohort across 11 centers, DCDD heart transplantation using TA-NRP with static cold storage achieved 30-day and 1-year outcomes comparable to DNDD hearts. The composite of 1-year death or severe primary graft failure was similar, and causal adjustment by inverse probability weighting confirmed no excess risk with DCDD hearts.

Key Findings

  • Primary composite outcome at 1 year was similar: 21.4% (DCDD) vs 22.2% (DNDD), P=0.87.
  • 30-day survival 94.9% vs 93.7% and 1-year survival 88.8% vs 87.3% for DCDD vs DNDD (P=0.70).
  • Severe primary graft failure: 13.3% (DCDD) vs 15.0% (DNDD), P=0.67.
  • Inverse probability weighting showed no association between DCDD and higher risk (HR 0.97, 95% CI 0.58–1.62, P=0.91).

Clinical Implications

Cardiac anesthesia and transplant teams can consider TA-NRP with static cold storage for DCDD donors, standardizing protocols for anticoagulation, perfusion management, and organ assessment, with expectation of comparable short-term outcomes to DNDD hearts.

Why It Matters

This provides robust real-world evidence that TA-NRP with static cold storage enables safe DCDD heart transplantation with outcomes matching DNDD, potentially expanding the donor pool without compromising results.

Limitations

  • Observational, nonrandomized design leaves potential residual confounding.
  • Short-term outcomes reported; longer-term graft durability not assessed.

Future Directions

Evaluate long-term survival and graft function, standardize TA-NRP protocols across systems, and compare TA-NRP vs direct procurement with ex-situ perfusion platforms.

Study Information

Study Type
Cohort
Research Domain
Treatment/Prognosis
Evidence Level
II - Prospective multicenter observational comparison with adjusted analyses.
Study Design
OTHER